PHASE I TRIAL OF AdRS Vtk VIRUS WITH GANCICLOVIR IN 
PATIENTS WITH UNRESECTABLE MALIGNANT 
MESOTHELIOMA 
UPCC 2594 
PREGNANCY AND FERTILITY CONCERNS: 
Patients that are pregnant or lactating are not eligible for this study. Fertile men or women must use 
effective contraception to be eligible for this study. 
WITHDRAWING FROM THE STUDY: 
My participation in this project is voluntary. I may refuse to participate in or withdraw from the 
study at any time without penalty or loss of benefits to which I may otherwise be entitled. In case I 
decide to withdraw from the study, I may suffer the following consequences: 1. Loss of ability to 
monitor for side effects of gene therapy. 2. Failure to find out if there are any unforeseen risks from 
gene therapy that may not be obvious without repeated evaluation. 
EXPECTED BENEFITS TO SUBJECTS OR TO OTHER 
I may not experience any benefit from participating in this study. If shrinkage of the tumor occurs, 
then I may benefit by a decrease in symptoms and tumor-related problems. 
It is hoped that much information will be learned which will guide further development of this new 
anti-cancer treatment 
CONFIDENTIALITY OF INFORMATION 
The principal investigator will keep a confidential record of your participation, which will be 
maintained and secured in the Clinical Research Center of the University of Pennsylvania Medical 
Center. Representatives of the National Institutes of Health, the Food and Drug Administration, or other 
regulatory agencies outside the University of Pennsylvania will have access to your records. My privacy 
will be protected by withholding my identity during any recording and reporting of this research except 
as required by law. The extreme amount of public interest in gene therapy may cause members of the 
media to try to find out who you are despite ail the precautions taken by and without the approval of the 
University of Pennsylvania Medical Center. If they succeed, I might be subject to frequent requests for 
interviews and my privacy may be reduced. Every effort will made to protect your privacy, but this may 
not be possible. 
ALTERNATIVES TO PARTICIPATION 
All appropriate alternative procedures available for mesothelioma patients, as well as their risks and 
benefits, will be discussed and explained to me. 
COST TO SUBJECT 
There will be no cost to me for in-patient care while on this study. Out-patient costs may or may not 
be covered by my third party payer. Any costs resulting from care I require as part of this study, or 
because of complications from this study not provided by my third party payer, will be provided by the 
Hospital of the University of Pennsylvania. 
COMPENSATION 
I am advised that no compensation will be provided to me as a result of my participation. 
Recombinant DNA Research, Volume 20 
[419] 
